139 related articles for article (PubMed ID: 38167649)
1. MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.
Xu K; Zheng X; Shi H; Ou J; Ding H
Sci Rep; 2024 Jan; 14(1):130. PubMed ID: 38167649
[TBL] [Abstract][Full Text] [Related]
2. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
Li L; Jiang P; Hu W; Zou F; Li M; Rao T; Ruan Y; Yu W; Ning J; Cheng F
J Transl Med; 2024 Mar; 22(1):295. PubMed ID: 38515112
[TBL] [Abstract][Full Text] [Related]
3. The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma.
Liu Z; Wang S; Yu K; Chen K; Zhao L; Zhang J; Dai K; Zhao P
J Transl Med; 2023 Nov; 21(1):863. PubMed ID: 38017538
[TBL] [Abstract][Full Text] [Related]
4. Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis.
Marima R; Hull R; Penny C; Dlamini Z
Mutat Res Rev Mutat Res; 2021; 787():108376. PubMed ID: 34083040
[TBL] [Abstract][Full Text] [Related]
5. MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation.
Li Y; Li L; Chen M; Yu X; Gu Z; Qiu H; Qin G; Long Q; Fu X; Liu T; Li W; Huang W; Shi D; Kang T; Luo M; Wu X; Deng W
Mol Oncol; 2018 Mar; 12(3):391-405. PubMed ID: 29360267
[TBL] [Abstract][Full Text] [Related]
6. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer.
Rimkus C; Friederichs J; Rosenberg R; Holzmann B; Siewert JR; Janssen KP
Int J Cancer; 2007 Jan; 120(1):207-11. PubMed ID: 17044027
[TBL] [Abstract][Full Text] [Related]
7. Dynamic feature of mitotic arrest deficient 2-like protein 2 (MAD2L2) and structural basis for its interaction with chromosome alignment-maintaining phosphoprotein (CAMP).
Hara K; Taharazako S; Ikeda M; Fujita H; Mikami Y; Kikuchi S; Hishiki A; Yokoyama H; Ishikawa Y; Kanno SI; Tanaka K; Hashimoto H
J Biol Chem; 2017 Oct; 292(43):17658-17667. PubMed ID: 28887307
[TBL] [Abstract][Full Text] [Related]
8. CDH1 binds MAD2L2 in a Rev1-like pattern.
Pernicone N; Grinshpon S; Listovsky T
Biochem Biophys Res Commun; 2020 Oct; 531(4):566-572. PubMed ID: 32811646
[TBL] [Abstract][Full Text] [Related]
9. MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
Pernicone N; Peretz L; Grinshpon S; Listovsky T
Anticancer Res; 2020 Oct; 40(10):5471-5480. PubMed ID: 32988869
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin promotes siMAD2L2‑induced apoptosis in colon cancer cells.
Ma L; Li X; Zhao X; Sun H; Kong F; Li Y; Sui Y; Xu F
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278473
[TBL] [Abstract][Full Text] [Related]
11. MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair.
de Krijger I; Föhr B; Pérez SH; Vincendeau E; Serrat J; Thouin AM; Susvirkar V; Lescale C; Paniagua I; Hoekman L; Kaur S; Altelaar M; Deriano L; Faesen AC; Jacobs JJL
Nat Commun; 2021 Sep; 12(1):5421. PubMed ID: 34521823
[TBL] [Abstract][Full Text] [Related]
12. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5' end resection.
Boersma V; Moatti N; Segura-Bayona S; Peuscher MH; van der Torre J; Wevers BA; Orthwein A; Durocher D; Jacobs JJL
Nature; 2015 May; 521(7553):537-540. PubMed ID: 25799990
[TBL] [Abstract][Full Text] [Related]
13. Role of the WNT/β-catenin/ZKSCAN3 Pathway in Regulating Chromosomal Instability in Colon Cancer Cell lines and Tissues.
Cho YE; Kim JH; Che YH; Kim YJ; Sung JY; Kim YW; Choe BG; Lee S; Park JH
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012568
[TBL] [Abstract][Full Text] [Related]
14. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
[TBL] [Abstract][Full Text] [Related]
15. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.
Thériault BL; Pajovic S; Bernardini MQ; Shaw PA; Gallie BL
Int J Cancer; 2012 Apr; 130(8):1844-54. PubMed ID: 21618518
[TBL] [Abstract][Full Text] [Related]
16. Novel LncRNA ZFHX4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer.
Wang X; Wang Y; Sun F; Xu Y; Zhang Z; Yang C; Zhang L; Lou G
Front Oncol; 2022; 12():945518. PubMed ID: 35903691
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
[TBL] [Abstract][Full Text] [Related]
18. H4K20me2 distinguishes pre-replicative from post-replicative chromatin to appropriately direct DNA repair pathway choice by 53BP1-RIF1-MAD2L2.
Simonetta M; de Krijger I; Serrat J; Moatti N; Fortunato D; Hoekman L; Bleijerveld OB; Altelaar AFM; Jacobs JJL
Cell Cycle; 2018; 17(1):124-136. PubMed ID: 29160738
[TBL] [Abstract][Full Text] [Related]
19. MAD2L2 Promotes Open Chromatin in Embryonic Stem Cells and Derepresses the Dppa3 Locus.
Rahjouei A; Pirouz M; Di Virgilio M; Kamin D; Kessel M
Stem Cell Reports; 2017 Apr; 8(4):813-821. PubMed ID: 28330620
[TBL] [Abstract][Full Text] [Related]
20. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
